NASDAQ: AMAMAmbrx Biopharma Inc Stock
$11.50+0.30 (+2.68%)
Updated Sep 29, 2023
AMAM Price
$11.50
Fair Value Price
N/A
Market Cap
$713.83M
52 Week Low
$0.38
52 Week High
$16.86
P/E
-8.65x
P/B
2.85x
P/S
147.39x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.64M
Earnings
-$59.64M
Gross Margin
100%
Operating Margin
-1,054.36%
Profit Margin
-1,057.9%
Debt to Equity
0.12
Operating Cash Flow
-$55M
Beta
-0.5
Next Earnings
Oct 26, 2023
Ex-Dividend
N/A
Next Dividend
N/A
AMAM Overview
Ambrx Biopharma Inc. is a clinical-stage company developing engineered precision biologics using its proprietary expanded genetic code technology platform. It creates antibody-drug conjugate and immune-oncology conjugate candidates, including ARX788, ARX517, ARX305, and ARX822. Ambrx collaborates with multiple pharmaceutical companies in additional therapeutic areas, including metabolic disorders and cardiovascular disease. The company was incorporated in 2003 and is headquartered in La Jolla, CA.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AMAM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AMAM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AMAM is good value based on its book value relative to its share price (2.85x), compared to the US Biotechnology industry average (5.09x)
P/B vs Industry Valuation
AMAM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AMAM due diligence checks available for Premium users.
Be the first to know about important AMAM news, forecast changes, insider trades & much more!
AMAM News
Valuation
AMAM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-8.65x
Industry
13.67x
Market
12.37x
AMAM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.85x
Industry
5.09x
AMAM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AMAM's financial health
Profit margin
Revenue
$1.1M
Net Income
-$17.8M
Profit Margin
-1,587.4%
AMAM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AMAM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$279.9M
Liabilities
$29.6M
Debt to equity
0.12
AMAM's short-term assets ($241.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AMAM's short-term assets ($241.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AMAM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.2M
Investing
$9.2M
Financing
$82.7M
AMAM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AMAM vs Biotech Stocks
Ambrx Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.